The role of recombinant insulin-like growth factor I in the treatment of the short child

  title={The role of recombinant insulin-like growth factor I in the treatment of the short child},
  author={Arlan L. Rosenbloom},
  journal={Current Opinion in Pediatrics},
  • A. Rosenbloom
  • Published 1 August 2007
  • Medicine, Biology
  • Current Opinion in Pediatrics
Purpose of review Commercial preparations of recombinant human insulin-like growth factor I became available in 2005. Off-label use has been promoted because of the paucity of patients having approved indications; I review the background and rationale for such use. Recent findings Attempts to identify growth hormone unresponsiveness in children with idiopathic short stature have been nonproductive. Treatment with insulin-like growth factor I for unequivocal growth hormone insensitivity improves… 
Insulin-Like Growth Factor-I Deficiency in Children with Growth Hormone Insensitivity
  • S. Kemp
  • Medicine, Biology
  • 2012
Recombinant human IGF-I (mecasermin) is approved by the US FDA and the European Medicines Agency for the treatment of patients with severe primary IGF deficiency or for patients with GH1 gene deletion who have developed neutralizing antibodies to GH.
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Clinical features of severe primary IGFD, laboratory findings, and indications for treatment are discussed, and results of long-term therapy with rhIGF1 (mecasermin) in patients affected by severePrimary IGFD and possible side effects are explained.
IGF-1 Therapy in Children with Liver Dysfunction
It is important to focus on IGF- level in serum along with Growth hormone while treating a child with poor growth in chronic liver disease and after liver transplantation, and the role of IGF-1 therapy should also be considered for better growth and development.
Insulin-Like Growth Factor-I Treatment in Primary Growth Hormone Insensitivity: Effect of Recombinant Human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-Binding Protein-3 Complex
This study confirms that rhIGF-I is effective in promoting growth in children with GHIS, and describes the long-term effect of various IGF-I preparations in a single subject treated for more than 14 years while focusing on height, height velocity as well as on additional auxological and laboratory data.
Role of insulin, insulin‐like growth factor‐1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris
Persistent acne in adulthood with high IGF‐1 levels may be considered as an indicator for increased risk of cancer, which may require appropriate dietary intervention as well as treatment with insulin‐sensitizing agents.
Postprandial Hyperglycemia Corrected by IGF-I (Increlex®) in Laron Syndrome
A Moroccan girl referred for short stature at 7 years and 8 months of age had dwarfism, hypoglycemia, and truncal obesity, and postprandial hyperglycemia is a metabolic consequence of chronic IGF-I deficiency.
The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders
[Growth hormone and idiopathic short stature].
Anaphylactic Reaction to Recombinant Insulin-like Growth Factor-I
A 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy is reported.


Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS).
  • Patricia Park, P. Cohen
  • Medicine, Biology
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2005
Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure
  • R. Clark
  • Biology, Medicine
    Pediatric Nephrology
  • 2004
In children with primary IGFD, where there is no GH signaling, recombinant human (rh)IGF-1 produces a large growth response, while in children who are GH and IGF-1 deficient, treatment with rhGH is the most-appropriate therapy.
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Treatment with rhIGF-I stimulates linear growth in children with severe IGF-I deficiency due to GH insensitivity, and adverse events are common but are rarely of sufficient severity to interrupt or modify treatment.
Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.
It is concluded that IGF-I (40 micrograms/kg every 12 h) given sc to adults with GHRD is safe; achieves normal levels of IGF- I; reduces insulin, IGF-II, and GH levels; and increases IGFBP-2 concentrations and urinary excretion of calcium.
Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
The growth response and favorable trough levels of IGF-I despite the overall lack of increase in circulating IGFBP-3 levels suggest an alternative mechanism for sustaining IGF- I levels and avoiding rapid clearance of rhIGF-I.
Controversy in clinical endocrinology: problems with reclassification of insulin-like growth factor I production and action disorders.
  • P. Cohen
  • Medicine, Biology
    The Journal of clinical endocrinology and metabolism
  • 2006
CONTEXT Recent developments in the IGF field have raised questions on whether this is the right time to redefine IGF deficiency. OBJECTIVE In this controversy, arguments are made against the need
Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure.
ALS is critical for maintaining normal serum concentrations of IGF-I and IGFBP-3, most likely by prolonging the half-lives of both proteins, and results support a modest role for the ternary complex in the regulation of stature.
Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
It is demonstrated that the rhIGF-I/rhIGFBP-3 complex was effective in increasing levels of circulating total and free IGF-I into the normal range for a 24-h period after a single sc administration in patients with GHIS, and that administration of rhigF- I/rhigF BP-3 was safe and well tolerated.
Normal growth and development in the absence of hepatic insulin-like growth factor I.
  • S. Yakar, J. Liu, D. Leroith
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
The somatomedin hypothesis proposed that insulin-like growth factor I (IGF-I) was a hepatically derived circulating mediator of growth hormone and is a crucial factor for postnatal growth and